An assessment of the formulation of a myricetin-loaded nanoemulsion for the management of diabetic wound healing in laboratory animals

Abstract

Within the class of flavonoids, myricetin is regarded as a flavonol. Recent studies have shown that myricetin may 
treat diabetes, cancer, and heart disease in diverse ways. There have been claims that myricetin is an antioxidant 
that is stronger than quercetin. The current research looked at how myricetin-loaded nanoemulsion (MYCT-NE) 
gel formulation affected diabetic animals' ability to repair wounds. The impact of myricetin-loaded nanoemulsion 
on diabetic wound healing was assessed using wound contraction measurement, hydroxyproline estimate, protein 
estimation, antioxidant test, and histological examination. The nanoemulsion gel was created using carbopol 934. 
A shorter length of epithelialization was seen on day 18 of therapy, indicating that the MYCT-NE gel treated groups 
had faster wound healing as compared to the control group. enhanced hydroxyproline levels in MYCT-NE geltreated tissue demonstrated enhanced collagen turnover, which accelerated the healing of wounds. After therapy 
and healing, the wound tissues' levels of catalase, glutathione, and superoxide dismutase (SOD), GSH, and other 
antioxidants are restored by MYCT-NE gel, demonstrating its potent antioxidant action. The findings demonstrated 
that the wound treated with MYCT-NE gel and the reference group without edema and congestion demonstrated 
effective original tissue regeneration. The current study's findings suggest that MYCT-NE gel reduces oxidative 
state in experimental animals, which speeds up the healing of cutaneous diabetic wounds.